Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 at Increased Risk of Progressing to Severe Illness

NCT05689034 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

1096

Enrollment

OTHER

Sponsor class

Conditions

COVID-19 Respiratory Infection

Interventions

DRUG: Azvudine
DRUG: Placebo

Sponsor

Peking Union Medical College Hospital